



## Kara Davis

Assistant Professor of Pediatrics (Hematology/Oncology)

Pediatrics - Hematology & Oncology

### CLINICAL OFFICE (PRIMARY)

- **Pediatric Hematology and Oncology**

1000 Welch Rd Ste 300

MC 5798

Palo Alto, CA 94304

**Tel** (650) 723-5535

**Fax** (650) 723-5231

### ACADEMIC CONTACT INFORMATION

- **Alternate Contact**

Alyssa Ray - Research Administrator

**Email** alyssar@stanford.edu

### Bio

---

#### BIO

Kara Davis, D.O. is an Assistant Professor of Pediatrics in the Division of Hematology and Oncology. Dr. Davis obtained her B.A. from Pennsylvania State University and her D.O. from the Philadelphia College of Osteopathic Medicine. Clinically, she completed her training in Pediatrics at Thomas Jefferson University/A.I. DuPont Children's Hospital and her Heme/Onc fellowship at Lucile Packard Children's Hospital at Stanford. During her fellowship training, Kara worked in the laboratory of Garry Nolan, Ph.D. where she utilized single-cell, high-dimensional analysis platforms to study healthy human B cell development and B cell leukemia. Her research focuses on using single-cell analysis to organize tumor heterogeneity in pediatric cancers, especially blood cancers, as means to determine cell populations associated with clinical risks such as relapse. Clinically, Dr. Davis sees patients with leukemia and is involved with the Cancer Cellular Therapies program with experience in treating children with chimeric antigen receptor (CAR) T-cells and other immunotherapies including checkpoint inhibitors.

#### CLINICAL FOCUS

- Pediatric Hematology-Oncology

#### ACADEMIC APPOINTMENTS

- Assistant Professor - University Medical Line, Pediatrics - Hematology & Oncology
- Member, Bio-X
- Member, Maternal & Child Health Research Institute (MCHRI)
- Member, Stanford Cancer Institute

#### ADMINISTRATIVE APPOINTMENTS

- Vice Chair, COG Study ADVL1412, Children's Oncology Group, (2016- present)

#### HONORS AND AWARDS

- Anne T. and Robert M. Bass Endowed Faculty Scholar in Pediatric Cancer and Blood Diseases, Stanford Maternal and Child Health Research Institute (2018)
- Zelencik Scientist, Harriet and Mary Zelencik Endowed Fund for Faculty Support in Children's Cancer and Blood Diseases (2021)

## PROFESSIONAL EDUCATION

- Fellowship: Stanford University Pediatric Hematology Oncology Fellowship (2010) CA
- Residency: AI Dupont Hospital for Children (2007) DE
- Medical Education: Philadelphia College of Osteopathic Medicine Office of the Registrar (2004) PA
- Board Certification: Pediatric Hematology-Oncology, American Board of Pediatrics (2011)
- Board Certification: Pediatrics, American Board of Pediatrics (2007)

## LINKS

- Lab Website: <http://med.stanford.edu/kldavislab.html>

## Research & Scholarship

---

### CURRENT RESEARCH AND SCHOLARLY INTERESTS

To address the intrinsic heterogeneity of primary cancers, we have taken a single-cell approach to the study of cancer, particularly childhood leukemia. To organize the tremendous data generated from single-cell studies, we also seek to understand the healthy structure of the tissue of origin.

Using single-cell, high-parameter analysis platforms, especially mass cytometry, to examine primary patient samples, we seek to identify how childhood cancers diverge from their healthy tissue of origin and how cancer cells may exploit developmental states for their benefit. Further, what populations or features of tumor cells are associated with clinical outcomes of interest, such as site of disease, relapse, or drug resistance? Using this knowledge, we can further investigate new approaches to treatment for children with cancer and mechanisms of drug resistance, and with a particular interest in how this relates to immunotherapeutic approaches to cancer treatment.

### CLINICAL TRIALS

- CAR-T Long Term Follow Up (LTFU) Study, Recruiting
- Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas, Recruiting
- Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies, Recruiting
- Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients, Recruiting
- Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia, Not Recruiting
- Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients., Not Recruiting
- Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients, Not Recruiting
- Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients, Not Recruiting
- Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL), Not Recruiting

## Teaching

---

### STANFORD ADVISEES

#### Postdoctoral Faculty Sponsor

Abhishek Koladiya, Chiara Pirillo, Catherine Yao

#### Doctoral Dissertation Reader (NonAC)

Hana Ghanim, Kwat Medetgul-Emar

## Publications

### PUBLICATIONS

- **Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion Following Loss of B-Cell Aplasia in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia: HESTER Phase II Study**  
Boyer, M. W., Chaudhury, S., Davis, K. L., Driscoll, T., Grupp, S. A., Hermiston, M., John, S., Keating, A. K., Kovacs, C., Myers, G., Phillips, C. L., Pulsipher, M. A., Talano, et al  
CIG MEDIA GROUP, LP.2021: S262-S263
- **CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.** *Nature medicine*  
Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., Frank, M. J., Shiraz, P., Sahaf, B., Craig, J., Iglesias, M., Younes, S., Natkunam, et al  
2021
- **GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas.**  
Majzner, R. G., Ramakrishna, S., Mochizuki, A., Patel, S., Chinnasamy, H., Yeom, K., Schultz, L., Richards, R., Campen, C., Reschke, A., Mahdi, J., Toland, A., Baggott, et al  
AMER ASSOC CANCER RESEARCH.2021
- **SINGLE CELL RNA SEQUENCING FROM THE CSF OF SUBJECTS WITH H3K27M+DIPG/DMG TREATED WITH GD2 CAR T-CELLULAR THERAPY**  
Mochizuki, A., Ramakrishna, S., Good, Z., Patel, S., Chinnasamy, H., Yeom, K., Schultz, L., Richards, R., Campen, C., Reschke, A., Mahdi, J., Toland, A., Baggot, et al  
OXFORD UNIV PRESS INC.2021: 39
- **GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG**  
Majzner, R., Ramakrishna, S., Mochizuki, A., Patel, S., Chinnasamy, H., Yeom, K., Schultz, L., Richards, R., Campen, C., Reschke, A., Mahdi, J., Martin, A., Toland, et al  
OXFORD UNIV PRESS INC.2021: 49-50
- **Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement.** *The Laryngoscope*  
Sidell, D. R., Balakrishnan, K., Best, S. R., Zur, K., Buckingham, J., De Alarcon, A., Baroody, F. M., Bock, J. M., Boss, E. F., Bower, C. M., Campisi, P., Chen, S. F., Clarke, et al  
2021
- **Mass Cytometry of Hematopoietic Cells.** *Methods in molecular biology (Clifton, N.J.)*  
Jager, A., Sarno, J., Davis, K. L.  
2021; 2185: 65–76
- **Cancer Informatics for Cancer Centers: Scientific Drivers for Informatics, Data Science, and Care in Pediatric, Adolescent, and Young Adult Cancer.** *JCO clinical cancer informatics*  
Kerlavage, A. R., Kirchhoff, A. C., Guidry Auvil, J. M., Sharpless, N. E., Davis, K. L., Reilly, K., Reaman, G., Penberthy, L., Deapen, D., Hwang, A., Durbin, E. B., Gallotto, S. L., Aplenc, et al  
2021; 5: 881-896
- **Use of cardiac radiation therapy as bridging therapy to CAR-T for relapsed pediatric B-cell acute lymphoblastic leukemia.** *Pediatric blood & cancer*  
Marquez, C. P., Montiel-Esparza, R., Hui, C., Schultz, L. M., Davis, K. L., Hoppe, R. T., Donaldson, S. S., Ramakrishna, S., Hiniker, S. M.  
2020: e28870
- **Use of Chimeric Antigen Receptor Modified T Cells With Extensive Leukemic Myocardial Involvement** *JACC: CARDIOONCOLOGY*  
Han, B., Montiel-Esparza, R., Chubb, H., Kache, S., Schultz, L. M., Davis, K. L., Ramakrishna, S., Su, L.  
2020; 2 (4): 666–70
- **Use of Chimeric Antigen Receptor Modified T Cells With Extensive Leukemic Myocardial Involvement.** *JACC. CardioOncology*  
Han, B., Montiel-Esparza, R., Chubb, H., Kache, S., Schultz, L. M., Davis, K. L., Ramakrishna, S., Su, L.  
2020; 2 (4): 666-670
- **Multiplexed ion beam imaging to describe tumor-immune microenvironment and tumor heterogeneity in neuroblastoma.**  
Kammersgaard, M. B., Bosse, M., Martinez, D., Bosse, K. R., Maris, J. M., Mackall, C. L., Angelo, R. M., Davis, K. L.

---

AMER ASSOC CANCER RESEARCH.2020

- **Integration of mechanistic immunological knowledge into a machine learning pipeline improves predictions** *NATURE MACHINE INTELLIGENCE*  
Culos, A., Tsai, A. S., Stanley, N., Becker, M., Ghaemi, M. S., McIlwain, D. R., Fallahzadeh, R., Tanada, A., Nassar, H., Espinosa, C., Xenochristou, M., Ganio, E., Peterson, et al  
2020
- **Integration of mechanistic immunological knowledge into a machine learning pipeline improves predictions.** *Nature machine intelligence*  
Culos, A., Tsai, A. S., Stanley, N., Becker, M., Ghaemi, M. S., McIlwain, D. R., Fallahzadeh, R., Tanada, A., Nassar, H., Espinosa, C., Xenochristou, M., Ganio, E., Peterson, et al  
2020; 2 (10): 619-628
- **Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report.** *Journal for immunotherapy of cancer*  
Schultz, L., Patel, S., Davis, K. L., Ramakrishna, S., Sahaf, B., Bhatia, N., Baggott, C., Erickson, C., Majzner, R. G., Oak, J., Bertaina, A., Mackall, C., Feldman, et al  
2020; 8 (2)
- **Progressive B Cell Loss in Revertant X-SCID.** *Journal of clinical immunology*  
Lin, C. H., Kuehn, H. S., Thauland, T. J., Lee, C. M., De Ravin, S. S., Malech, H. L., Keyes, T. J., Jager, A., Davis, K. L., Garcia-Lloret, M. I., Rosenzweig, S. D., Butte, M. J.  
2020
- **Validation of a model of pediatric leukemia based on pluripotent stem cells using mass cytometry**  
Domingo-Reines, J., Kimmey, S., Vijayaragavan, K., Bosse, M., Bendall, S., Davis, K., Ramos-Mejia, V.  
AMER ASSOC CANCER RESEARCH.2020: 95
- **Using single-cell, high-dimensional approaches to unravel tumor heterogeneity in pediatric cancer**  
Davis, K. L.  
AMER ASSOC CANCER RESEARCH.2020: 29–30
- **A Cancer Biologist's Primer on Machine Learning Applications in High-Dimensional Cytometry.** *Cytometry. Part A : the journal of the International Society for Analytical Cytology*  
Keyes, T. J., Domizi, P., Lo, Y., Nolan, G. P., Davis, K. L.  
2020
- **Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia.** *Current oncology reports*  
Barsan, V., Ramakrishna, S., Davis, K. L.  
2020; 22 (2): 11
- **Supercharging your CAR.** *Blood*  
Ramakrishna, S. n., Davis, K. L.  
2020; 135 (9): 593–94
- **CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.** *Blood*  
Baird, J. H., Frank, M. J., Craig, J. n., Patel, S. n., Spiegel, J. Y., Sahaf, B. n., Oak, J. S., Younes, S. n., Ozawa, M. n., Yang, E. n., Natkunam, Y. n., Tamaresis, J. S., Ehlinger, et al  
2020
- **Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADV1412): a multicentre, open-label, single-arm, phase 1-2 trial.** *The Lancet. Oncology*  
Davis, K. L., Fox, E. n., Merchant, M. S., Reid, J. M., Kudgus, R. A., Liu, X. n., Minard, C. G., Voss, S. n., Berg, S. L., Weigel, B. J., Mackall, C. L.  
2020
- **RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit.** *Oncotarget*  
Chae, H. D., Dutta, R. n., Tiu, B. n., Hoff, F. W., Accordi, B. n., Serafin, V. n., Youn, M. n., Huang, M. n., Sumarsono, N. n., Davis, K. L., Lacayo, N. J., Pigazzi, M. n., Horton, et al  
2020; 11 (25): 2387–2403
- **Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.** *The Lancet. Oncology*

- Laetsch, T. W., Myers, G. D., Baruchel, A., Dietz, A. C., Pulsipher, M. A., Bittencourt, H., Buechner, J., De Moerloose, B., Davis, K. L., Nemecek, E., Driscoll, T., Mechinaud, F., Boissel, et al  
2019
- **Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia** *CANCER RESEARCH*  
Diaz-Flores, E., Comeaux, E. Q., Kim, K. L., Melnik, E., Beckman, K., Davis, K. L., Wu, K., Akutagawa, J., Bridges, O., Marino, R., Wohlfeil, M., Braun, B. S., Mullighan, et al  
2019; 79 (9): 2339–51
  - **BCL-2 is a Therapeutic Target For Hypodiploid B-Lineage Acute Lymphoblastic Leukemia.** *Cancer research*  
Diaz-Flores, E., Comeaux, E. Q., Kim, K. L., Melnik, E. M., Beckman, K., Davis, K. L., Wu, K., Akutagawa, J., Bridges, O., Marino, R., Wohlfeil, M., Braun, B. S., Mullighan, et al  
2019
  - **A novel platform for isotype-specific testing of autoantibodies.** *PLoS one*  
Carter, K. L., Treurnicht, A., Davis, K. L., Kumar, R. B., Feldman, B. J.  
2019; 14 (2): e0211596
  - **High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cells.** *Blood advances*  
Jeong, J. n., Jager, A. n., Domizi, P. n., Pavel-Dinu, M. n., Gojenola, L. n., Iwasaki, M. n., Wei, M. C., Pan, F. n., Zehnder, J. L., Porteus, M. H., Davis, K. L., Cleary, M. L.  
2019; 3 (19): 2825–35
  - **Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells**  
Chae, H., Murphy, L. C., Donato, M., Lee, A. G., Sweet-Cordero, E., Abidi, P., Bittencourt, H., Lacayo, N. J., Dahl, G., Aftandilian, C., Davis, K. L., Huang, M., Sumarsono, et al  
AMER SOC HEMATOLOGY.2018
  - **Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia**  
Grupp, S. A., Maude, S. L., Rives, S., Baruchel, A., Boyer, M. W., Bittencourt, H., Bader, P., Buchner, J., Laetsch, T. W., Stefanski, H., Myers, G., Qayed, M., Pulsipher, et al  
AMER SOC HEMATOLOGY.2018
  - **1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL)**  
Schultz, L. M., Davis, K. L., Baggott, C., Chaudry, C., Marcy, A., Mavroukakis, S., Sahaf, B., Kong, K. A., Muffly, L. S., Kim, S., Meyer, E. H., Fry, T. J., Qin, et al  
AMER SOC HEMATOLOGY.2018
  - **Glucocorticoids-Resistant Leukemic B-Cells Undergo a Phenotypic Change That Increases Sensitivity to SRC/ABL Inhibition**  
Sarno, J., Pedersen, C., Jager, A., Burns, T., Gaipa, G., Nolan, G. P., Bava, A., Davis, K. L.  
AMER SOC HEMATOLOGY.2018
  - **Chromatin Remodeling Therapy and Capizzi Methotrexate in Treatment-Related MDS/AML**  
Aftandilian, C., Sakamoto, K. M., Davis, K. L., Dahl, G., Lacayo, N. J.  
AMER SOC HEMATOLOGY.2018
  - **Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Lin, J. K., Lerman, B. J., Barnes, J. I., Boursiquot, B. C., Tan, Y. J., Robinson, A. Q., Davis, K. L., Owens, D. K., Goldhaber-Fiebert, J. D.  
2018: JCO2018790642
  - **Individualized drug combination based on single-cell drug perturbations**  
Anchang, B., Davis, K., Fienberg, H., Bendall, S., Karacosta, L., Nolan, G., Plevritis, S. K.  
AMER ASSOC CANCER RESEARCH.2018
  - **False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy** *BLOOD*  
Laetsch, T. W., Maude, S. L., Milone, M. C., Davis, K. L., Krueger, J., Cardenas, A., Eldjerou, L. K., Keir, C. H., Wood, P. A., Grupp, S. A.  
2018; 131 (23): 2596–98

- **SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia.** *Oncotarget*  
Sarno, J., Savino, A. M., Buracchi, C., Palmi, C., Pinto, S., Bugarin, C., Jager, A., Bresolin, S., Barber, R. C., Silvestri, D., Israeli, S., Dyer, M. J., Cazzaniga, et al  
2018; 9 (33): 22872–85
- **Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse.** *Nature medicine*  
Good, Z., Sarno, J., Jager, A., Samusik, N., Aghaepour, N., Simonds, E. F., White, L., Lacayo, N. J., Fantl, W. J., Fazio, G., Gaipa, G., Biondi, A., Tibshirani, et al  
2018; 24 (4): 474–83
- **Publisher Correction: High-resolution myogenic lineage mapping by single-cell mass cytometry.** *Nature cell biology*  
Porpiglia, E., Samusik, N., Van Ho, A. T., Cosgrove, B. D., Mai, T., Davis, K. L., Jager, A., Nolan, G. P., Bendall, S. C., Fantl, W. J., Blau, H. M.  
2018
- **Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia** *NEW ENGLAND JOURNAL OF MEDICINE*  
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., Qayed, M., De Moerloose, B., Hiramatsu, et al  
2018; 378 (5): 439–48
- **Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways** *ONCOTARGET*  
Chae, H., Cox, N., Dahl, G. V., Lacayo, N. J., Davis, K. L., Capolicchio, S., Smith, M., Sakamoto, K. M.  
2018; 9 (4): 4301–17
- **DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity.** *Proceedings of the National Academy of Sciences of the United States of America*  
Anchang, B. n., Davis, K. L., Fienberg, H. G., Williamson, B. D., Bendall, S. C., Karacosta, L. G., Tibshirani, R. n., Nolan, G. P., Plevritis, S. K.  
2018; 115 (18): E4294–E4303
- **Single-cell mass cytometry and machine learning predict relapse in childhood leukemia.** *Molecular & cellular oncology*  
Sarno, J., Davis, K. L.  
2018; 5 (5): e1472057
- **Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia** *Journal of Clinical Oncology*  
Lin, J., Lerman, B. J., Barnes, J., Boursiquot, B., Tan, Y., Robinson, A., Davis, K., Owens, D., Goldhaber-Fiebert, J.  
2018
- **Identity and Diversity of Human Peripheral Th and T Regulatory Cells Defined by Single-Cell Mass Cytometry** *JOURNAL OF IMMUNOLOGY*  
Kunicki, M. A., Hernandez, L., Davis, K. L., Bacchetta, R., Roncarolo, M.  
2018; 200 (1): 336–46
- **High-resolution myogenic lineage mapping by single-cell mass cytometry** *NATURE CELL BIOLOGY*  
Porpiglia, E., Samusik, N., Van Ho, A. T., Cosgrove, B. D., Mai, T., Davis, K. L., Jager, A., Nolan, G. P., Bendall, S. C., Fantl, W. J., Blau, H. M.  
2017; 19 (5): 558-?
- **New developments in immunotherapy for pediatric solid tumors.** *Current opinion in pediatrics*  
Schultz, L. M., Majzner, R. n., Davis, K. L., Mackall, C. n.  
2017
- **Checkpoint inhibition in pediatric hematologic malignancies** *PEDIATRIC HEMATOLOGY AND ONCOLOGY*  
Davis, K. L., Agarwal, A. M., Verma, A. R.  
2017; 34 (6-7): 379–94
- **Immunotherapy for acute lymphoblastic leukemia: from famine to feast** *BLOOD ADVANCES*  
Davis, K. L., Mackall, C. L.  
2016; 1 (3): 265–69
- **Automated mapping of phenotype space with single-cell data** *NATURE METHODS*  
Samusik, N., Good, Z., Spitzer, M. H., Davis, K. L., Nolan, G. P.  
2016; 13 (6): 493-?
- **Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis** *CELL*

---

Levine, J. H., Simonds, E. F., Bendall, S. C., Davis, K. L., Amir, E. D., Tadmor, M. D., Litvin, O., Fienberg, H. G., Jager, A., Zunder, E. R., Finck, R., Gedman, A. L., Radtke, et al  
2015; 162 (1): 184-197

- **The Split Virus Influenza Vaccine rapidly activates immune cells through Fc gamma receptors** *VACCINE*  
O'Gorman, W. E., Huang, H., Wei, Y., Davis, K. L., Leipold, M. D., Bendall, S. C., Kidd, B. A., Dekker, C. L., Maecker, H. T., Chien, Y., Davis, M. M.  
2014; 32 (45): 5989-5997
- **The Split Virus Influenza Vaccine rapidly activates immune cells through Fc $\gamma$  receptors.** *Vaccine*  
O'Gorman, W. E., Huang, H., Wei, Y., Davis, K. L., Leipold, M. D., Bendall, S. C., Kidd, B. A., Dekker, C. L., Maecker, H. T., Chien, Y., Davis, M. M.  
2014; 32 (45): 5989-5997
- **Single-Cell Trajectory Detection Uncovers Progression and Regulatory Coordination in Human B Cell Development** *CELL*  
Bendall, S. C., Davis, K. L., Amir, E. D., Tadmor, M. D., Simonds, E. F., Chen, T. J., Shenfeld, D. K., Nolan, G. P., Pe'er, D.  
2014; 157 (3): 714-725
- **viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia.** *Nature biotechnology*  
Amir, E. D., Davis, K. L., Tadmor, M. D., Simonds, E. F., Levine, J. H., Bendall, S. C., Shenfeld, D. K., Krishnaswamy, S., Nolan, G. P., Pe'er, D.  
2013; 31 (6): 545-552
- **Pediatric Acute Myeloid Leukemia as Classified Using 2008 WHO Criteria: A Single-Center Experience.** *American journal of clinical pathology*  
Davis, K. L., Marina, N., Arber, D. A., Ma, L., Cherry, A., Dahl, G. V., Heerema-McKenney, A.  
2013; 139 (6): 818-825
- **Ikaros: master of hematopoiesis, agent of leukemia.** *Therapeutic advances in hematology*  
Davis, K. L.  
2011; 2 (6): 359-368
- **Speeding the Flow Toward Personalized Therapy in Childhood Acute Leukemia** *PEDIATRIC BLOOD & CANCER*  
Simonds, E. F., Davis, K. L., Lacayo, N. J.  
2009; 53 (4): 525-526
- **Why Are Young Infants Tested for Herpes Simplex Virus?** *PEDIATRIC EMERGENCY CARE*  
Davis, K. L., Shah, S. S., Frank, G., Eppes, S. C.  
2008; 24 (10): 673-678